Efficacy and safety of anlotinib in bevacizumab-pretreated patients with non-squamous non-small cell lung cancer (AN-BELIEF study): a multicenter retrospective study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Given the growing population of patients with disease progression following bevacizumab-based regimens, effective post-bevacizumab antiangiogenic options remain an unmet need. We aimed to evaluate the efficacy and safety of anlotinib in this specific population of non-squamous non-small cell lung cancer (NSCLC). Methods: This multicenter retrospective cohort study enrolled patients from six hospitals between January 2018 and May 2024. Eligible patients had non-squamous NSCLC and received bevacizumab-containing treatment, or received anlotinib monotherapy without prior bevacizumab exposure. Key exclusions included anlotinib initiation before bevacizumab treatment, the use of other antiangiogenic tyrosine kinase inhibitors after bevacizumab, or insufficient radiologic evaluation. Patients were grouped by prior bevacizumab exposure and subsequent treatment. Tumor response was assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, with progression-free survival (PFS) as the primary endpoint; secondary endpoints included the objective response rate (ORR) and disease control rate (DCR), and adverse events (AEs), with AEs assessed according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results: 5.23 months; HR 0.82, P=0.048). Conclusions: Anlotinib showed clinical activity in this selected retrospective cohort of bevacizumab-pretreated patients with non-squamous NSCLC. Anlotinib-based combination therapy was associated with longer PFS than other subsequent therapies after adjustment for baseline differences; however, these findings require confirmation in larger prospective studies.
Institutions: Tongji University, Shanghai Pulmonary Hospital, Nanfang Hospital, Southern Medical University, Sun Yat-sen University, Sun Yat-sen Memorial Hospital, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Shanghai Jiao Tong University, Renji Hospital, First Affiliated Hospital of Soochow University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W7222428522